Metropolitan Life Insurance CO Ventyx Biosciences, Inc. Transaction History

Metropolitan Life Insurance CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$1.9 - $10.13 $4,900 - $26,125	2,579 New	2,579 $14,000
Q3 2023 Nov 14, 2023	BUY	$29.8 - $40.3 $5,393 - $7,294	181 Added 7.03%	2,755 $95,000
Q2 2023 Aug 10, 2023	BUY	$28.53 - $39.55 $35,434 - $49,121	1,242 Added 93.24%	2,574 $84,000
Q1 2023 May 15, 2023	SELL	$29.51 - $46.65 $5,311 - $8,397	-180 Reduced 11.9%	1,332 $44,000
Q4 2022 Jun 14, 2023	BUY	$24.16 - $36.38 $4,348 - $6,548	180 Added 13.51%	1,512 $49.6 Million
Q3 2022 Jun 14, 2023	BUY	$12.64 - $38.7 $2,275 - $6,966	180 Added 13.51%	1,512 $52.8 Million
Q2 2022 Jun 20, 2023	BUY	$11.95 - $18.75 $2,151 - $3,375	180 Added 13.51%	1,512 $18,000
Q2 2022 Aug 11, 2022	BUY	$11.95 - $18.75 $18,068 - $28,350	1,512 New	1,512 $18,000

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $132M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.